NAD+ is a coenzyme that transfers hydrogen ions and participates in many enzymatic reactions. It is composed of ribosyl nicotinamide 5'-diphosphate coupled to 5'-adenosine phosphate through a pyrophosphate bond[1]. NAD+ is the oxidized form of nicotinamide adenine dinucleotide (NAD), and the reduced form of NAD is NADH. The intracellular NAD+/NADH reflects the metabolic activity and health of the cell[2]. NAD+ is a key redox carrier that plays an irreplaceable role in glycolysis, gluconeogenesis, tricarboxylic acid cycle and respiratory chain[3]. NAD+ is also a substrate of the nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1)[4].
In vitro, NAD+ (100µM) treatment of naive CD4+ T cells for 72h induced naive CD4+ T cells to produce a large amount of cytokines, promoted cell differentiation into helper T cells (Th1, Th2 and Th17 cells), but prevented differentiated cells from producing cytokines[5].
In vivo, intravenous administration of NAD+ (10, 60 mg/kg) to ART2−/− and wild-type (WT) mice reduced the inhibitory effect of CD4+ CD25+ FoxP3+ regulatory T cells (T reg cells) in WT mice in a dose-dependent manner, but had no effect on the T reg cell function in ART2−/− mice. It also regulated the size and phenotype of the T reg cell pool in vivo[6]. Intravenous administration of NAD+ (10-20 mg/kg) to rats subjected to ischemia/reperfusion (I/R) dose-dependently reduced I/R-induced myocardial infarction, reduced the levels of TUNNEL signaling, Box and cleaved caspase-3, and increased Bcl-XL levels[7].
References:
[1] Pietrowska-Borek M, Dobrogojski J, Sobieszczuk-Nowicka E, et al. New insight into plant signaling: extracellular ATP and uncommon nucleotides[J]. Cells, 2020, 9(2): 345.
[2] Belenky P, Bogan K L, Brenner C. NAD+ metabolism in health and disease[J]. Trends in biochemical sciences, 2007, 32(1): 12-19.
[3] Guo C, Huang Q, Wang Y, et al. Therapeutic application of natural products: NAD+ metabolism as potential target[J]. Phytomedicine, 2023, 114: 154768.
[4] Alano C C, Tran A, Tao R, et al. Differences among cell types in NAD+ compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes[J]. Journal of neuroscience research, 2007, 85(15): 3378-3385.
[5] Tullius S G, Biefer H R C, Li S, et al. NAD+ protects against EAE by regulating CD4+ T-cell differentiation[J]. Nature communications, 2014, 5(1): 5101.
[6] Hubert S, Rissiek B, Klages K, et al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2–P2X7 pathway[J]. Journal of Experimental Medicine, 2010, 207(12): 2561-2568.
[7] Zhang Y, Wang B, Fu X, et al. Exogenous NAD+ administration significantly protects against myocardial ischemia/reperfusion injury in rat model[J]. American journal of translational research, 2016, 8(8): 3342.
NAD+是一种转递氢离子的辅酶，参与许多酶促反应，由核糖基烟酰胺5'-二磷酸通过焦磷酸键与5'-磷酸腺苷偶联组成[1]。NAD+是氧化形式的烟酰胺腺嘌呤二核苷酸（NAD），NAD还原形式为NADH，细胞内NAD+/NADH反映了细胞的代谢活性和健康状况[2]。NAD+是一种关键的氧化还原载体，它在糖酵解、糖异生、三羧酸循环及呼吸链中发挥着不可替代的作用[3]。NAD+也是核酶聚（ADP-核糖）聚合酶-1（PARP-1）的底物[4]。
在体外，NAD+（100µM）处理幼稚CD4+ T细胞72h，诱导幼稚CD4+ T细胞产生大量细胞因子，促进细胞分化为辅助T细胞（Th1、Th2和Th17细胞），但阻止分化细胞产生细胞因子[5]。
在体内，NAD+（10， 60mg/kg）通过静脉注射处理ART2−/−和野生型（WT）小鼠，以剂量依赖性方式降低了WT小鼠CD4+ CD25+ FoxP3+调节性T细胞 （T reg 细胞）的抑制作用，而对ART2−/−小鼠的T reg细胞功能没有影响，还可以调节体内T reg细胞池的大小和表型[6]。NAD+（10-20mg/kg）通过静脉注射治疗缺血/再灌注（I/R）大鼠，剂量依赖性地减少I/R诱发的心肌梗塞，降低TUNNEL信号、Box和裂解caspase-3的水平，并增加Bcl-XL水平[7]。